《新股表現》飛鶴(06186.HK)暗盤開報7.8元 高上市價4%
根據輝立交易平台顯示,明天掛牌的中國飛鶴(06186.HK)暗盤高開4%報7.8元,最多升6.7%高見8元遇阻,掉頭低見7.29元,現造7.4元,較上市價7.5元,低1.3%,成交565萬股。
飛鶴是內地最大兼廣為人所知的中國品牌嬰幼兒配方奶粉生產商。是次來港上市共發售8.9334億股,其中10%公開發售獲逾12倍超購,認購一手中籤率65%;股份以招股範圍(7.5-10元)下限定價,料集資淨額65.64億元,主要用作還債、潛在併購、建設加拿大金斯頓廠房,以及用作海外嬰幼兒配方奶粉和營養補充品研發活動等。上市聯席保薦人分別為摩通、招商證券及建銀國際。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.